The Often-Missed Corner of Healthcare That Wall Street Is Loving Danaher (NYSE:DHR) reported better-than-expected second-quarter 2026 results, with management citing accelerating core revenue growth, stronger life sciences demand and benefits from productivity initiatives, while…
so addressing investor concerns over delayed bioprocessing shipments. President and Chief Executive Officer Rainer M
Blair said the company delivered “better-than-expected revenue, earnings, and cash flow” in the quarter. He said core growth improved from the first quarter, supported by commercial execution, recent product launches and recovering end markets. – An AI Play Hiding in Plain Sight: A Look at Johnson Controls Danaher reported second-quarter sales of $6.3 billion. Core revenue increased 3% year over year, while core growth excluding respiratory testing revenue rose 4.5%, representing a 150-basis-point acceleration from the first quarter.
Adjusted diluted net earnings per common share were $1.94, up about 8% year over year. The company generated $1.3 billion in free cash flow during the quarter and $2.4 billion in the first half, with year-to-date free cash flow to net income conversion of 124%. Blair said demand from large pharma and biopharma customers remained healthy, biotech funding improved, academic and government markets largely stabilized, and clinical and applied markets continued to be sources of strength.